Monopar Therapeutics (MNPR) Net Income towards Common Stockholders Growth (3y) (2020 - 2025)
Monopar Therapeutics (MNPR) Net Income towards Common Stockholders Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 144.84% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -20.99% |
| Jun 30, 2025 | 3.27% |
| Mar 31, 2025 | -9.38% |
| Sep 30, 2024 | 15.65% |
| Jun 30, 2024 | 5.13% |
| Mar 31, 2024 | 3.47% |
| Sep 30, 2023 | -5.84% |
| Jun 30, 2023 | -17.06% |
| Mar 31, 2023 | -29.92% |
| Dec 31, 2022 | -52.38% |
| Sep 30, 2022 | -46.48% |
| Jun 30, 2022 | -44.33% |
| Mar 31, 2022 | -19.85% |
| Dec 31, 2021 | -58.40% |
| Sep 30, 2021 | -53.86% |
| Jun 30, 2021 | -45.26% |
| Mar 31, 2021 | -27.23% |
| Dec 31, 2020 | -62.67% |
| Sep 30, 2020 | 52.00% |
| Jun 30, 2020 | -35.01% |